{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:14:45Z","timestamp":1711559685438},"reference-count":57,"publisher":"Japan Society for Clinical Immunology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2177\/jsci.38.403","type":"journal-article","created":{"date-parts":[[2016,1,3]],"date-time":"2016-01-03T17:04:51Z","timestamp":1451840691000},"page":"403-411","source":"Crossref","is-referenced-by-count":1,"title":["Plasmablast in the pathology of multiple sclerosis"],"prefix":"10.2177","volume":"38","author":[{"given":"Masakazu","family":"NAKAMURA","sequence":"first","affiliation":[{"name":"Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"ARAKI","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, NCNP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"YAMAMURA","sequence":"additional","affiliation":[{"name":"Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP)"},{"name":"Multiple Sclerosis Center, NCNP"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Comabella, M., Khoury, S.J.: Immunopathogenesis of multiple sclerosis. Clin Immunol<\/i>. 142<\/b>: 2-8, 2012.","DOI":"10.1016\/j.clim.2011.03.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Compston, A., Coles, A.: Multiple sclerosis. Lancet<\/i>. 372<\/b>: 1502-1517, 2008.","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"3","unstructured":"3) Polman, C.H., et al.: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol<\/i>. 69<\/b>: 292-302, 2011."},{"key":"4","unstructured":"4) Duddy, M., et al.: Managing MS in a changing treatment landscape. J Neurol<\/i>. 258<\/b>: 728-739, 2011."},{"key":"5","unstructured":"5) Lucchinetti, C., et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol<\/i>. 47<\/b>: 707-717, 2000."},{"key":"6","unstructured":"6) Keegan, M., et al.: Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet<\/i>. 366<\/b>: 579-582, 2005."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Killestein, J., Polman, C.H.: Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol<\/i>. 7<\/b>: 221-228, 2011.","DOI":"10.1038\/nrneurol.2011.22"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sormani, M.P., De Stefano, N.: Defining and scoring response to IFN-beta in multiple sclerosis. Nat Rev Neurol<\/i>. 9<\/b>: 504-512, 2013.","DOI":"10.1038\/nrneurol.2013.146"},{"key":"9","unstructured":"9) Sbardella, E., et al.: Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. BMC Neurol<\/i>. 9<\/b>: 54, 2009."},{"key":"10","unstructured":"10) Comabella, M., et al.: A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain<\/i>. 132<\/b>: 3353-3365, 2009."},{"key":"11","unstructured":"11) van Baarsen, L.G., et al.: Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One<\/i>. 3<\/b>: e1927, 2008."},{"key":"12","unstructured":"12) Rudick, R.A., et al.: Excessive biologic response to IFNbeta is associated with poor treatment response in patients with multiple sclerosis. PLoS One<\/i>. 6<\/b>: e19262, 2011."},{"key":"13","unstructured":"13) Wandinger, K.P., et al.: TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet<\/i>. 361<\/b>: 2036-2043, 2003."},{"key":"14","unstructured":"14) Zula, J.A., et al.: The role of cell type-specific responses in IFN-beta therapy of multiple sclerosis. Proc Natl Acad Sci U S A<\/i>. 108<\/b>: 19689-19694, 2011."},{"key":"15","unstructured":"15) Axtell, R.C., et al.: T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med<\/i>. 16<\/b>: 406-412, 2010."},{"key":"16","unstructured":"16) Bushnell, S.E., et al.: Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology<\/i>. 79<\/b>: 531-537, 2012."},{"key":"17","unstructured":"17) Hartung, H.P., et al.: Interleukin 17F level and interferon beta response in patients with multiple sclerosis. JAMA Neurol<\/i>. 70<\/b>: 1017-1021, 2013."},{"key":"18","unstructured":"18) Hiepe, F. et al.: Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol<\/i>. 7<\/b>: 170-178, 2011."},{"key":"19","unstructured":"19) Shimizu, J., et al.: IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology<\/i>. 75<\/b>: 1423-1427, 2010."},{"key":"20","unstructured":"20) Kira, J., et al.: Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol<\/i>. 40<\/b>: 569-574, 1996."},{"key":"21","unstructured":"21) Lennon, V.A., et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet<\/i>. 364<\/b>: 2106-2112, 2004."},{"key":"22","unstructured":"22) Lennon, V.A., et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med<\/i>. 202<\/b>: 473-477, 2005."},{"key":"23","unstructured":"23) Wingerchuk, D.M., et al.: The spectrum of neuromyelitis optica. Lancet Neurol<\/i>. 6<\/b>: 805-815, 2007."},{"key":"24","unstructured":"24) Chihara, N., et al.: Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A<\/i>. 108<\/b>: 3701-3706, 2011."},{"key":"25","unstructured":"25) Uzawa, A., et al.: Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler<\/i>. 16<\/b>: 1443-1452, 2010."},{"key":"26","unstructured":"26) Araki, M., et al.: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology<\/i>. 82<\/b>: 1302-1306, 2014."},{"key":"27","unstructured":"27) Chihara, N., et al.: Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One<\/i>. 8<\/b>: e83036, 2013."},{"key":"28","unstructured":"28) Qin, Y., et al.: Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest<\/i>. 102<\/b>: 1045-1050, 1998."},{"key":"29","unstructured":"29) Owens, G.P., et al.: Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol<\/i>. 43<\/b>: 236-243, 1998."},{"key":"30","unstructured":"30) Baranzini, S.E., et al.: B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol<\/i>. 163<\/b>: 5133-5144, 1999."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Colombo, M., et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol<\/i>. 164<\/b>: 2782-2789, 2000.","DOI":"10.4049\/jimmunol.164.5.2782"},{"key":"32","unstructured":"32) Palanichamy, A., et al.: Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med<\/i>. 6<\/b>: 248ra106, 2014."},{"key":"33","unstructured":"33) Elliott, C., et al.: Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain<\/i>. 135<\/b>: 1819-1833, 2012."},{"key":"34","unstructured":"34) Serafini, B., et al.: Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol<\/i>. 14<\/b>: 164-174, 2004."},{"key":"35","unstructured":"35) Magliozzi, R., et al.: A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol<\/i>. 68<\/b>: 477-493, 2010."},{"key":"36","unstructured":"36) Kikuchi, Y., et al.: RP105-lacking B cells from lupus patients are responsible for the production of immunoglobulins and autoantibodies. Arthritis Rheum<\/i>. 46<\/b>: 3259-3265, 2002."},{"key":"37","unstructured":"37) Jacobi, A.M., et al.: HLA-DRhigh\/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis<\/i>. 69<\/b>: 305-308, 2010."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kurtzke, J.F.: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology<\/i>. 33<\/b>: 1444-1452, 1983.","DOI":"10.1212\/WNL.33.11.1444"},{"key":"39","unstructured":"39) Kinnunen, T., et al.: Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest<\/i>. 123<\/b>: 2737-2741, 2013."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Crotty, S.: T follicular helper cell differentiation, function, and roles in disease. Immunity<\/i>. 41<\/b>: 529-542, 2014.","DOI":"10.1016\/j.immuni.2014.10.004"},{"key":"41","unstructured":"41) Linterman, M.A., et al.: Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med<\/i>. 17<\/b>: 975-982, 2011."},{"key":"42","unstructured":"42) Matsushita, T., et al.: Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci<\/i>. 291<\/b>: 37-43, 2010."},{"key":"43","unstructured":"43) Lublin, F.D., Reingold, S.C.: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology<\/i>. 46<\/b>: 907-911, 1996."},{"key":"44","unstructured":"44) Yednock, T.A., et al.: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature<\/i>. 356<\/b>: 63-66, 1992."},{"key":"45","unstructured":"45) Matloubian, M., et al.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature<\/i>. 427<\/b>: 355-360, 2004."},{"key":"46","unstructured":"46) Villar, L.M., et al.: Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol<\/i>. 69<\/b>: 191-197, 2012."},{"key":"47","unstructured":"47) Min, J.H., et al.: Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler<\/i>. 18<\/b>: 113-115, 2012."},{"key":"48","unstructured":"48) Nakamura, M., et al.: Differential effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler<\/i>. 20<\/b>: 1371-1380, 2014."},{"key":"49","unstructured":"49) Nicoletti, F., et al.: Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine<\/i>. 12<\/b>: 682-687, 2000."},{"key":"50","unstructured":"50) Satoh, J., et al.: Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol<\/i>. 6<\/b>: 18, 2006."},{"key":"51","unstructured":"51) Bellido, T., et al.: Transcriptional activation of the p21 (WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem<\/i>. 273<\/b>: 21137-21144, 1998."},{"key":"52","unstructured":"52) Morse, L., et al.: Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18 (INK4c) and IL-6. Immunity<\/i>. 6<\/b>: 47-56, 1997."},{"key":"53","unstructured":"53) Dang, V.D., et al.: From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol<\/i>. 28<\/b>: 77-83, 2014."},{"key":"54","unstructured":"54) Matsumoto, M., et al.: Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity<\/i>. 41<\/b>: 1040-1051, 2014."},{"key":"55","unstructured":"55) Schneider, A., et al.: In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T (regs) involves IL-6-mediated signaling. Sci Transl Med<\/i>. 5<\/b>: 170ra115, 2013."},{"key":"56","unstructured":"56) Trinschek, B., et al.: Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoS One<\/i>. 8<\/b>: e77634, 2013."},{"key":"57","unstructured":"57) Hauser, S.L., et al.: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med<\/i>. 358<\/b>: 676-688, 2008."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u591a\u767a\u6027\u786c\u5316\u75c7\u75c5\u614b\u306b\u304a\u3051\u308b\u30d7\u30e9\u30ba\u30de\u30d6\u30e9\u30b9\u30c8"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/38\/5\/38_403\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:29:42Z","timestamp":1567470582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/38\/5\/38_403\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.38.403","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}